Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On December 5, 2024, MediciNova, Inc. (MNOV) announced a study update and interim analysis from the Phase 2b/3 COMBAT-ALS trial were scheduled to be presented at the 35th International Symposium on ALS/MND.</li><li>As of Nov.</li><li>15, 2024, 217 participants had been enrolled and 183 participants were assigned to either MN-166 or placebo.</li></ul>

On December 5, 2024, MediciNova, Inc. (MNOV) announced a study update and interim analysis from the Phase 2b/3 COMBAT-ALS trial were scheduled to be presented at the 35th International Symposium on ALS/MND.As of Nov.15, 2024, 217 participants had been enrolled and 183 participants were assigned to either MN-166 or placebo.

MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial 